Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. has garnered a positive outlook due to significant regulatory progress for its OST-HER2 treatment, which has been elevated to a Type B pre-BLA meeting by the FDA, indicating a strong alignment towards potential Accelerated Approval. The company's successful Phase 2b trial data demonstrating statistically significant improvements in event-free survival and overall survival in pulmonary metastatic osteosarcoma further supports its development efforts and potential market viability. Additionally, the multiple regulatory designations for OST-HER2, including orphan and fast track status, are anticipated to expedite its review process, enhancing OS Therapies' strategic positioning as it approaches its planned submission and targets for accelerated market access by late 2026.

Bears say

OS Therapies Inc's financial report reveals a significant increase in operating loss, rising to $28.75 million in 2025 from $8.82 million in 2024, highlighting a growing burden from development and regulatory expenses. This escalating cost structure raises concerns about the company's financial sustainability as it attempts to advance its pipeline of product candidates. Furthermore, the heightened expenditure on broader corporate infrastructure may limit available resources for critical research and development, negatively impacting the firm’s future growth prospects.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.